Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Summary

Open-label, Phase 2, single treatment arm, 3 cohorts

Timeline

Start

2019-03-13

Primary completion

2021-04-09

Completion

2021-04-23

Publications

• Ye L, Chen X, Zhou F. EGFR-mutant NSCLC: emerging novel drugs. Curr Opin Oncol. 2021 Jan;33(1):87-94. doi: 10.1097/CCO.0000000000000701.

Drugs

Indications